[1]
|
Weimm, Z. (2016) Long Non-Coding RNA Sand Their Roles in Non-Small Cell Lung Cancer. Genomics Proteomics Bioinformatics, 14, 280-288. https://doi.org/10.1016/j.gpb.2016.03.007
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.
https://doi.org/10.3322/caac.21442
|
[3]
|
陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(1): 1-14.
|
[4]
|
He, X.R., Han, S.Y. and Li, P.P. (2017) Recent Highlights of Chinese Medicine for Advanced Lung Cancer. Chinese Journal of Integrative Medicine, 23, 323-330. https://doi.org/10.1007/s11655-016-2736-2
|
[5]
|
Mok, T.S., Wu, Y.L., Thongprasert, S., et al. (2016) Gefitinib or Carboplatin-Paclitaxelin Pulmonary Adenocarcinoma. Oncotarget, 7, 41691-41702.
|
[6]
|
Mok, T.S., Wu, Y.L., Thongprasert, S., et al. (2009) Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. The New England Journal of Medicine, 361, 947-957. https://doi.org/10.1056/NEJMoa0810699
|
[7]
|
Zhou, C., Wu, Y.L., Chen, G., et al. (2011) Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study. The Lancet Oncology, 12, 735-742.
https://doi.org/10.1016/S1470-2045(11)70184-X
|
[8]
|
Wu, Y.L., Zhou, C., Liam, C.K., et al. (2015) First-Line Erlotinib versus Gemcitabine/Cisplatin in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Analyses from the Phase III, Randomized, Open-Label, ENSURE Study. Annals of Oncology, 26, 1883-1889. https://doi.org/10.1093/annonc/mdv270
|
[9]
|
Miller, V.A., Hirsh, V., Cadranel, J., et al. (2012) Afatinib versus Placebo for Patients with Advanced, Metastatic Non-Small Cell Lung Cancer after Failure of Erlotinib, Gefitinib, or Both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial. The Lancet Oncology, 13, 528-538.
https://doi.org/10.1016/S1470-2045(12)70087-6
|
[10]
|
Janne, P.A., Ou, S.H., Kim, D.W., et al. (2014) Dacomitinib as First-Line Treatment in Patients with Clinically or Molecularly Selected Advanced Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 15, 1433-1441. https://doi.org/10.1016/S1470-2045(14)70461-9
|
[11]
|
Mok, T.S., Wu, Y.L., Ahn, M.J., et al. (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine, 76, 629-640. https://doi.org/10.1056/NEJMoa1612674
|
[12]
|
J?nne, P.A., Yang, J.C., Kim, D.W., et al. (2015) AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 1689-1699. https://doi.org/10.1056/NEJMoa1411817
|
[13]
|
Yang, J., Ramalingam, S.S., J?nne, P.A., et al. (2016) LBA2-PR: Osimertinib (AZD9291) in Pre-Treated PTS with T790M Positive Advanced NSCLC: Updated Phase 1 (P1) and Pooled Phase 2 (P2) Results. Journal of Thoracic Oncology, 11, S152-S153. https://doi.org/10.1016/S1556-0864(16)30325-2
|
[14]
|
Soria, J.C., Ohe, Y., Vansteenkiste, J., et al. (2018) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medi-cine, 378, 113-125. https://doi.org/10.1056/NEJMoa1713137
|
[15]
|
徐婷, 孙大兴. 非小细胞肺癌的中医药治疗进展[J]. 浙江中医杂志, 2011, 46(8): 614-617.
|
[16]
|
刘嘉湘. 辨证治疗原发性肺癌 310 例疗效分析[J]. 上海中医药杂志, 1985(10): 3-5.
|
[17]
|
刘嘉湘. 益肺抗瘤饮治疗 271 例非小细胞肺癌临床观察[J]. 上海中医药杂志, 2001, 35(2): 4-6.
|
[18]
|
康小红, 王丽芳, 王中奇, 等. 肺炎宁方延缓 TKIs 靶向治疗晚期肺腺癌耐药的临床观察[J]. 新中医, 2012, 44(9): 52-54.
|
[19]
|
张梅, 张慧敏. 益气通络解毒方联合 EGFR-TKI 靶向治疗非小细胞肺癌的临床研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2014: 35.
|
[20]
|
房芳, 陈红, 赵辉, 等. 吉非替尼联合平消胶囊治疗中晚期非小细胞肺癌的临床观察[J]. 中国现代医学杂志, 2011, 21(7): 883-886.
|
[21]
|
贾英杰, 黄敏娜, 孙一予, 等. 厄洛替尼联合消岩汤加减方治疗非小细胞肺癌的临床观察[J]. 中国医药指南, 2011, 9(35): 23-24.
|
[22]
|
尤建良. 晚期肺癌靶向治疗时中医药的切入[J]. 辽宁中医杂志, 2006, 33(10): 1228-1229.
|
[23]
|
周晓蓉, 徐士玲, 刘建红, 等. 复方锡类散液保留灌肠治疗化疗引起的严重腹泻[J]. 临床肿瘤学杂志, 2005, 10(5): 540-541.
|
[24]
|
张琇文, 邵怿, 张欣欣, 等. 参苓白术颗粒联合吉非替尼/厄罗替尼治疗脾气虚型晚期非小细胞肺癌临床研究[J]. 新中医, 2014, 46(1): 127-129.
|
[25]
|
王雄文, 陈日辉. 23 例吉非替尼相关皮疹中医辨证治疗分析[J]. 内蒙古中医药, 2008, 27(24): 9-10.
|
[26]
|
梁翠微, 杨兵, 杜均祥, 等. 吉非替尼相关皮疹的中医辨证论治[J]. 中国实用医药, 2011, 6(16): 22-23.
|
[27]
|
邱玉梅. 裴氏黄白散治疗易瑞沙所致皮肤不良反应的疗效观察[J]. 西部中医药, 2012, 25(11): 80-82.
|